mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Deming, Dustin A ^a   Leystra, Alyssa A ^a   Farhoud, Mohammed ^b   Nettekoven, Laura ^a   Clipson, Linda ^a   Albrecht, Dawn ^a   Washington, Mary Kay ^c   Sullivan, Ruth ^d   Weichert, Jamey P ^d   Halberg, Richard B ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN P110; PROTEIN PIK3CA; PROTEIN S6; RAPAMYCIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPSY; CANCER INVASION; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLLOID CARCINOMA; COLON CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVATION; FEMALE; MALE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLON; COLONIC NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NECROSIS; PHOSPHATIDYLINOSITOL 3-KINASES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MUS;

EID: 84876067024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060709     Document Type: Article

References (33)

1. Markowitz SD, Bertagnolli MM, (2009) Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460.
2. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. J Clin Oncol 27: 2091-2096.
3. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, et al. (2010) Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targ Oncol 5: 19-28.
4. American Cancer Society (2011) Cancer Facts & Figures 2011. Atlanta: American Cancer Society.
5. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, et al. (2009) PIK3CA mutationsin human solid tumors. Role in sensitivity to various therapeutic approaches. Cell Cycle 8: 1352-1358.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
7. Zhao L, Vogt PK, (2010) Hot-spot mutations in p100α of phosphatidylinositol 3-kinase (PI3K). Differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9: 596-600.
8. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
9. Leystra A, Deming D, Zahm C, Farhoud M, Olson TJ, et al. (2012) Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res 72: 2931-2936.
10. Saam JR, Gordon JI, (1999) Inducible gene knockouts in the small intestinal and colonic epithelium. J Biol Chem 274: 38071-38082.
11. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, et al. (2009) PI3 kinase signals BCR-dependent mature B cell survival. Cell 139: 573-586.
12. Durkee BY, Mudd SR, Roen CN, Clipson L, Newton MA, et al. (2008) Reproducibility of tumor volume measurement at microCT colonography in living mice. Acad Radiol 15: 334-341.
13. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
14. Stelzer MK, Pitot HC, Liem AL, Lee D, Kennedy GD, et al. (2010) Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res 3: 1542-1551.
15. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Samera L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
17. Pal SK, Figlin RA, Reckamp K, (2010) Targeted therapies for non-small cell lung cancer: An evolving landscape. Mol Cancer Ther 9: 1931-1944.
18. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Soloman B, et al. (2011) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
19. Chabner BA, (2011) Early accelerated approval for highly targeted cancer drugs. N Engl J Med 364: 1087-1089.
20. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, et al. (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30: 777-782.
21. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, et al. (2008) PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia 10: 534-541.
22. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
23. Chung J, Kuo CJ, Crabtree GR, Blenis J, (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69: 1227-1236.
24. Hauge C, Frodin M, (2006) RSK and MSK in MAP kinases signaling. J Cell Sci 119: 3021-3023.
25. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinae pathway. Mol Cell Biol 24: 3112-3124.
26. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14062.
27. Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR, (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106: 1386-1394.
28. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, et al. (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 18: 2515-2525.
29. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18: 2316-2325.
30. Hernandez-Aya LF, Gonzalez-Angulo AM, (2011) Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16: 404-414.
31. Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, et al. (2010) PI3Kα inhibitors that inhibit metastases. Oncotarget 1: 339-348.
32. Wong KK, Engelman JA, Cantley LC, (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87-90.
33. Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell J, et al. (2012) Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res 72: Supplement 1.